TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Summary

This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.

Timeline

Start

2026-03-31

Primary completion

2028-03-31

Completion

2030-03-31

Drugs

Indications